4503   Astellas Pharma Inc.

09/24/2024 08:30	Astellas Receives Approval from the EC for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
09/03/2024 15:00	Notice Regarding Issuance of Unsecured Bonds
08/01/2024 15:00	Notice Regarding Change in fair value of contingent consideration
08/01/2024 15:00	Presentation Material for Information Meeting (Q1/FY2024)
08/01/2024 15:00	Supplementary Documents (Q1/FY2024)
08/01/2024 15:00	Financial Results (Q1/FY2024)
07/29/2024 08:30	Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and GJ Cancer
07/29/2024 08:30	Astellas Receives Positive CHMP Opinion for PADCEV in combination with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
07/04/2024 17:00	Corporate Governance Report
05/28/2024 08:00	Notice of Convocation of the 19th Term Annual Shareholders Meeting
05/15/2024 16:00	Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme for the Domestic and Global Astellas Group Executives
05/15/2024 16:00	Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
04/25/2024 15:00	Presentation Material for Information Meeting (FY2023)
04/25/2024 15:00	Supplementary Documents (FY2023)
04/25/2024 15:00	Financial Results (FY2023)
04/25/2024 15:00	Change of Directors
04/25/2024 15:00	Change in Definition of Core Basis in Financial Results
04/22/2024 08:30	Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction Against the Generic Versions of Myrbetriq
04/12/2024 16:00	Notice Regarding Impairment Loss for intangible assets, Change in fair value of contingent consideration, and Revision of Financial Forecasts for FY23
03/25/2024 08:30	Astellas Receives Positive CHMP Opinion for XTANDITM in Additional Recurrent Early Prostate Cancer Treatment Setting
02/21/2024 08:30	Presentation Material for Sustainability Meeting
02/05/2024 15:00	Financial Results (Q3/FY2023)
02/05/2024 15:00	Supplementary Documents (Q3/FY2023)
02/05/2024 15:00	Presentation Material for Information Meeting (Q3/FY2023)
01/31/2024 11:00	Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First Line Treatment of Advanced Bladder Cancer
01/29/2024 08:30	EMA Validates Type II Variation Application for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
01/09/2024 08:30	Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
12/26/2023 11:00	Corporate Governance Report
12/22/2023 08:30	Astellas Completes Acquisition of Propella Therapeutics
12/18/2023 08:30	PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
12/01/2023 08:30	FDA Grants Priority Review for sBLA of PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
11/17/2023 15:00	Pfizer and Astellas' XTANDI Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
11/16/2023 08:30	Astellas to Acquire Propella Therapeutics
11/01/2023 15:00	Financial Results (Q2/FY2023)
11/01/2023 15:00	Supplementary Documents (Q2/FY2023)
11/01/2023 15:00	Presentation Material for Information Meeting (Q2/FY2023)
10/16/2023 08:30	Astellas Receives Positive CHMP Opinion for VEOZA(fezolinetant)